⌘K
Change language Switch ThemeSign In
Narrow Mode
The Convergence of AI and Biotechnology: The Rise of AI x Bio Teams ===================================================================
The Convergence of AI and Biotechnology: The Rise of AI x Bio Teams ===================================================================  ### Garry Tan
@garrytan
AI x Bio teams like Origin have coding agents, scaling laws, and a wave of big biotech deals all at their backs. This is barely touched territory. Crazy what this small team can do now.
#### Yash Rathod
@YashRathod_75 · 9h ago
Today, we're excited to release 10,000 fully AI-designed enhancer sequences for the research community. Axis was prompted to design sequences with targeted activity in one of three widely used cell-lines.
AI allows us to explore a vast design space, going beyond the natural genome.
00:17
6
22
135
43.4K
Mar 13, 2026, 9:11 PM View on X
22 Replies
15 Retweets
142 Likes
35.8K Views  Garry Tan @garrytan
One Sentence Summary
Garry Tan highlights the massive potential of small AI x Bio teams leveraging coding agents and scaling laws to disrupt biotechnology.
Summary
Garry Tan, CEO of Y Combinator, comments on the emerging 'AI x Bio' sector, specifically referencing a breakthrough by the Origin/Axis team who released 10,000 AI-designed enhancer sequences. He emphasizes that the combination of AI coding agents, scaling laws, and significant biotech deals is creating a 'barely touched territory' where small, agile teams can achieve outsized impact in drug discovery and genomic design beyond the natural genome.
AI Score
82
Influence Score 40
Published At Yesterday
Language
English
Tags
AI x Bio
Biotechnology
Scaling Laws
Coding Agents
Y Combinator HomeArticlesPodcastsVideosTweets
The Convergence of AI and Biotechnology: The Rise of AI x... ===============